Phase I/II trial of cabazitaxel plus abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and abiraterone

201627 citationsJournal Articlebronze Open Access

Authors

Good health and well-being

Published in: Annals of Oncology

Volume 28, Issue 1, pp. 90-95

Field-Weighted Citation Impact: 3.84